ÂÜÀòÂÒÂ×

Pushpa Shao, Ph.D., is a Senior Director of Regulatory CMC at BridgeBio since January 2023, overseeing regulatory strategy for multiple affiliates. Previously, Pushpa served as Director of Regulatory CMC at Turning Point Therapeutics, managing regulatory activities for precision oncology projects and authoring significant regulatory documents. Other roles include Associate Director of Regulatory CMC at Pacira Pharmaceuticals, Senior Manager at FibroGen, and experience as a consultant and in various regulatory affairs positions at companies like Halozyme Therapeutics and Pfizer. Pushpa holds a Ph.D. in Pharmaceutical Science from Rutgers University and advanced degrees from the University of Cincinnati and The Bombay College of Pharmacy.